1989年7月至今 于西安交通大学第一附属医院药学部从事临床药学及医院药事管理工作

1997年6-9月 于北京大学医学部临床药理研究所进修临床药理

2005年6-7月 卫生部公派参加新加坡《医院药事管理研讨班》

2009年9月-2010年8月 参加清华大学国际创新管理（医院药事管理）研究生课程进修班（第五期）

2011年-2012年 赴新加坡国立大学药学院作访问学者

2000年1月-2004年6月 任西安交通大学第一附属医院药剂科副主任

2004年6月-2015年2月 任西安交通大学第一附属医院药学部主任

2015年4月至今 任西安交通大学第一附属医院药学部学科带头人，兼科技部部长

主持国家自然科学基金3项，参与3项，指导国家自然科学基金青年基金5项；主持国家“十一五”、“十二五”科技支撑计划子课题3项，主持及参与省级项目13项。

1. 国家自然科学基金 项目起止年月：2017年1月-2021年 12月；项目名称：乳耐药靶标Transgelin2与PI3K/PTEN/Akt通路反馈作用参与乳腺癌侵袭转移的机制研究；项目编号：81672954；项目负责人：董亚琳。

2. 国家自然科学基金 项目起止年月：2015年1月-2018年 12月；项目名称：乳腺癌耐药分子标志物Transgelin2耐药功能与位点分析研究；项目编号：81473177；项目负责人：董亚琳。

3. 国家自然科学基金 项目起止年月：2010年1月-2012年12月；项目名称：《应用PF-2D分析技术筛选乳腺癌化疗耐药分子标志物的实验研究》；项目编号：30973673；项目负责人：董亚琳。

4. 国家自然基金青年基金 项目起止年月：2018年1月至-2020年 12月；项目名称：基于靶细胞PK/PD模型研究伏立康唑预防侵袭性曲霉菌病的机制及给药方案优化；项目编号：81703618；项目指导人：董亚琳。

5. 国家自然基金青年基金 项目起止年月：2013年1月-2015年12月；项目名称：基于中国重症感染患者利奈唑胺PPK/PD模型的耐药预测及临床治疗决研究；项目编号：81201490/H1511；项目指导人：董亚琳。

6. 国家十二五科技支撑计划重点课题 项目开展时间：2013年4月；项目名称：利奈唑胺、伊立替康及紫杉醇的综合评价研究；项目编号：2013BAI06B04Y023053；项目负责人：董亚琳。

7. 国家十一五科技支撑计划重点课题 项目开展时间：2010年6月；项目名称：基层医疗机构基本药物合理使用培训教材编写-呼吸系统疾病治疗药物的合理使用；项目编号：2009BAI76B030907；项目负责人：董亚琳。

8. 国家十一五科技支撑计划重点项目 项目开展时间：2009年11月；项目名称：基层医疗机构主要基本药物合理使用评价和研究；项目编号：2009BAI76B030219；项目负责人：董亚琳。

累计发表科研论文261篇，其中87篇被SCI收录。代表作如下：

1. Q. Yang, Y. Zhai, L Chen, T Zhang, Y. Yan, T. Meng, L. Liu, L. Chen, X. Wang, Y. Dong*. Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients. Acta Pharmacol Sin. 2018, 1(1): 1-11.

2. T. Wang, M. Yan, D. Tang, L. Xue, T. Zhang, Y. Dong, L. Zhu, X. Wang, Y. Dong*. Therapeutic Drug Monitoring and Safety of Voriconazole Therapy in Patients with Child-Pugh Class B and C Cirrhosis: A Multicenter Study. Int J Infect Dis. 2018, 72: 49-54.

3. S. Hu, T. Wang, H. You, S. Wei, H. Song, T. Zhang, D. Zhang, Y. Dong*. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens. Basic & Clinical Pharmacology & Toxicology. 2018.

4. L. Chen, Y. Wang, T. Zhang, Y. Li, T. Meng, L. Liu, R. Hao, Y. Dong*. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018, 18(1): 155.

5. T. Wang, T. Zhang, T. Meng, Y. Li, L. Chen, Q. Yang, Y. Dong, J. Lei, L. Chen, Y. Dong*. A Strategy for designing Voriconazole Dosage Regimens to Prevent Invasive Pulmonary Aspergillosis Based on a Cellular Pharmacokinetics /pharmacodynamics Model. Journal of Translational Medicine. 2018, 16(1): 157-166.

6. H. You, Y. Dong, Y. Zou, T. Zhang, J. Lei, L. Chen, X. Wang, Y. Dong*, T. Wang*. Voriconazole therapeutic drug monitoring: factors associated with supertherapeutic and subtherapeutic voriconazole concentrations. Int J Clin Pharmacol Ther. 2018, 56(5): 239-246.

7. Y. Zou, J. Lian, Y. Di, H. You, H. Yao, L. Liu, Y. Dong*. The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units. Int J Clin Pharm. 2018, 40(1): 175-182.

8. Y. Wang, Y. Xing, L. Chen, T. Meng, Y. Li, J. Xie, L. Chen, Y. Dong*, W. Dong*. Fluconazole versus mould‑active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost‑efectiveness analysis. International Journal of Hematology. Int J Hematol. 2018, 107: 235-243.

9. Y. Wang, J. Xie, Y. Xing, L. Chen, Y. Li, T. Meng, W. Dong, X. Wang, Y. Dong*. Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis. Antimicrobial Agents and Chemotherapy. 2017, 61(12): e00620-17.

10. T. Zhang, Y. Wang, Q. Yang, Y. Dong*. Procalcitonin-Guided Antibiotic Therapy in Critically Ill Adults: A Meta-analysis. BMC Infect Dis. 2017, 17(1): 514-525.

11. J. Xie, J. Roberts, A. Alobaid, C. Roger, Y. Wang, Q. Yang, J. Sun, H. Dong, X. Wang, X. Feng, J. Lipman, Y. Dong*. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Journal of Antimicrobial Chemotherapy. 2017, 61(8): 00345-17.

12. Y. Wang, Q. Yang, L. Chen, L. Liu, R. Hao, T. Zhang, X. Wang, J. Lei, J Xie, Y. Dong*. Cross-resistant of voriconazole and fluconazole non-albicans Candida infection in intensive care unit patients. European Journal of Clinical Microbiology & Infectious Diseases. 2017, 36(11): 2117-2126.

13. T. Wang, Q. Yang, Y. Li, T. Meng, Y. Wang, T. Zhang, J. Lei, J. Xing, Y. Dong*. Uptake and efflux kinetics, and intracellular activity of voriconazole against A. fumigatus in human pulmonary epithelial cells: a new challenge treating intracellular infection. Fundamental & Clinical Pharmacology. 2017, 31(3): 311-318.

14. T. Wang, Q. Yang, Y. Wang, Y. Li, T. Meng, L. Chen, J. Xie, J. Xing, Y. Dong*. Determination and Characterization of Uptake of Voriconazole in Human Lung Epithelial Cells by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Analytical letters. 2017, 50(2): 304-314.

15. H. Dong, J. Xie, T. Wang, L. Chen, X. Zeng, J. Sun, X. Wang, Y. Dong*. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. International Journal of Antimicrobial Agents. 2016, 48: 259-264.

16. Y. Wang, T. Wang, J. Xie, Q. Yang, X. Zheng, W. Dong, J. Xing, X. Wang, Y. Dong*. Correlation between Voriconazole Trough Plasma Concentration or CYP2C19 Genotypes and Hepatotoxicity in Intensive Care Unit Patients. Pharmacotherapy. 2016, 36(7): 757-765.

17. Q. Yang, T. Wang, J. Xie, Y. Wang, X. Zheng, L. Chen, Y. Li, T. Meng, Y. Dong*. Pharmacokinetic/pharmacodynamic adequacy of echinocandinsagainst Candida spp. in intensive care unit patients and generalpatient populations. International Journal of Antimicrobial Agents. 2016, 479(5): 397-402.

18. Q. Yang, T. Wang, J. Xie, Y. Wang, X. Zheng, L. Chen, X. Cheng, H. Dong, W. Dong, X. Zeng, X. Wang, Y. Dong*. A sensitive ultra-performance liquid chromatography-tandem mass spectrometry method to monitor caspofungin trough plasma concentrations and association between troughs and efficacy in intensive care unit patients. RSC Advances. 2015, 5: 104806-104814.

19. X. Zheng, C. Wang, Y. Xing, S. Chen, T. Meng, H. You, I. Ojima*, Y. Dong*. SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells. International Journal of Oncology. 2017, 50: 893-902.

20. J. Xie, Y. Wang, X. Zheng, Q. Yang, T. Wang, Y. Zou, J. Xing, Y. Dong*. Modeling and forecasting Acinetobacter baumannii resistance to set appropriate use of cefoperazone-sulbactam: Results from trend analysis of antimicrobial consumption and development of resistance in a tertiary care hospital. American Journal of Infection Control. 2015, 43(8): 861-864.

21. T. Wang, J. Xie, Y. Wang, X. Zheng, J. Lei, X. Wang, H. Dong, Q. Yang, L. Chen, J. Xing, Y. Dong*. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections. Pharmacotherapy. 2015, 35(9): 797-804.

22. T. Wang, N. Li, S. Hu, J. Xie, J. Lei, Y. Wang, X. Zheng, J. Xing, Y. Dong*. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. International Journal of Clinical Pharmacology and Therapeutics. 2015, 53(5): 356-362.

23. Y. Zou, Y. Ma, J. Liu, J. Shi, T. Fan, Y. Shan, H. Yao, Y. Dong*. Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009-2013). European Journal of Clinical Microbiology & Infectious Diseases. 2015, 34: 795-803.

24. Y. Wang, Y. Zou, J. Xie, T. Wang, X. Zheng, H. He, W. Dong, J. Xing, Y. Dong*. Linezolid versus Vancomycin for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: a systematic review with meta-analysis and cost-effectiveness analysis in China. European Journal of Clinical Pharmacology. 2015, 71: 107-115.

25. W. Zhang, J. Cai, S. Chen, X. Zheng, S. Hu, W. Dong, J. Lv, J. Xing, Y. Dong*. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. Mol Med Rep. 2015, 12(1): 1506-1514.

26. J. Cai, S. Chen, W. Zhang, X. Zheng, S. Hu, C. Pang, J. Lv, J. Xing, Y. Dong*. Salvianolic acid A reverses paclitaxel resistance in human breast cancer cells via targeting the expression of transgelin 2 and attenuating PI3K/Akt pathway. Phytomedicine. 2014, 21(12): 1725-1732.

27. T. Wang, H. Zhu, J. Sun, X. Cheng, J. Xie, H. Dong, L. Chen, X. Wang, J. Xing, Y. Dong*. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014, 44(5): 436-442.

28. S. Chen, Q. Dong, S. Hu, J. Cai, W. Zhang, J. Sun, T. Wang, J. Xie, H. He, J. Xing, J. Lv, Y. Dong*. Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells. Molecular Biosystems. 2014, 10(2): 294-303.

29. J. Xie, T. Wang, X. Wang, X. Cheng, H. Dong, Y. Wang, X. Zheng, L. Zhou, J. Xing, Y. Dong*. Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. Journal of Separation Science. 2014, 37(12): 1396-1403.

30. J. Xie, T. Wang, X. Wang, X. Cheng, H. Dong, Y. Wang, X. Zheng, L. Zhou, J. Xing, Y. Dong*. Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. Journal of Separation Science. 2014, 37(12): 1396-1403.